Reata Pharma shares jumped on Tuesday after the firm announced positive results from its midstage neuromuscular disorder drug trial.
Reata shares saw a solid gain on Monday after the company reported results from a couple midstage kidney trials.
The top analyst upgrades, downgrades and other research calls from Wednesday include Blackstone, Ciena, Merck, Tempur Sealy and Universal Display.
Reata Pharmaceuticals saw its shares make an incredible gain to kick off the week after it reported initial data from its mid-stage trial evaluating bardoxolone in patients with chronic kidney...
The pending holiday didn’t slow insiders from buying shares, and we continued to see some strong trading during the week.
The S&P 500 and Dow are pushing new highs as 2016 comes to a close. While the post-election tailwind has been incredibly strong, there are still companies holding back this rally.
Reata Pharmaceuticals has filed an S-1 form with the U.S. Securities and Exchange Commission for a secondary offering.
The number of initial public offerings (IPOs) in 2016 grew by five last week, with a food distribution company leading the way.
While all four of last week’s initial public offerings (IPOs) went out as scheduled, the results were tepid at best. Three of the four price below the mid-point of their expected ranges and the...
Reata Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Reata Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission regarding its initial public offering.
Reata Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Reata Pharmaceuticals has amended filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Reata Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).